Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP10 | P09238 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5463714 | 0.98 | DRD2 (0.46) | DRD2CHRNB2CHRNA4SIGMAR1MMP3 | |
| Hydrochloric Acid SCHEMBL5696604 | 0.98 | DRD2 (0.46) | DRD2CHRNB2CHRNA4SIGMAR1MMP3 | |
| SCHEMBL2280595 | 0.91 | CHRNB2 (0.42) | DRD2CHRNB2CHRNA4SIGMAR1MMP3 | |
| SCHEMBL23231746 | 0.85 | NNMT (0.41) | CHRNB2CHRNA4NNMTSCN9AALDH1A1 | |
| SCHEMBL5696495 | 0.85 | DRD2 (0.45) | DRD2SIGMAR1CCR2KCNH2GABRA5 | |
| SCHEMBL5183086 | 0.84 | ALDH1A1 (0.42) | CHRNB2CHRNA4NNMTSCN9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5462350 | 0.84 | DRD2 (0.44) | DRD2SIGMAR1CCR2KCNH2GABRA5 | |
| Hydrochloric Acid SCHEMBL5696549 | 0.84 | DRD2 (0.44) | DRD2SIGMAR1CCR2KCNH2GABRA5 | |
| SCHEMBL5696675 | 0.82 | DRD2 (0.43) | DRD2SIGMAR1ALDH1A1GABRA5 | |
| Hydrochloric Acid SCHEMBL5462013 | 0.81 | DRD2 (0.42) | DRD2SIGMAR1ALDH1A1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| CN-101952286-A | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions | ASTRAZENECA AB | 2011-01-19 | — | — | CN | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | PFIZER, INC. | 2007-01-25 | — | — | US | disclosed |
| EP-1673366-A1 | 1-\"2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL]-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035522-A1 | 1-‘2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL!-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | GRIN1, GRIN3A, GRIN2C | DRD2 283/4885CHRNB2 334/4885CHRNA4 184/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | DRD2 4077/4885CHRNB2 1324/4885CHRNA4 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.